About the company
PROMOMED is a leading innovative biopharmaceutical company
Thanks to this, PROMOMED implements the concept of a full production cycle, responds promptly to the current needs of the industry, and also implements the latest technologies to create innovative medicines.
R&D
Own, modern and unique world-class research center Research & Development Hub
We are responding to critical medical challenges: creating new ones, anticipating the future, and finding solutions
The Company's portfolio
It includes blockbuster drugs and innovative biotechnological drugs that have no analogues on the Russian market.
The company is developing a diversified portfolio of more than 360 medicines in the TOP 10 segments of the pharmaceutical market.
Based on its own developments, the Company produces drugs for the treatment of socially significant diseases: oncology, diabetes, obesity, neurology, infectious diseases, rheumatology, etc.
Own R&D center
The core of breakthrough healthcare solutions and the foundation of the Company's business development
It includes laboratories for the development of finished medicines (biotechnological and small molecule-based) and the development of pharmaceutical substances, an analytical laboratory, a registration service, and a production transfer coordination center.
There is also a quality control service that covers the entire cycle from the development and production of medicines to their consumption.
history
2025
January
The Federal Center for the Development of Biotechnologies and Medicine has started work at the Ogarev Mordovian State University.
The scientific facility, which is strategic for the country, was created on behalf of Russian President Vladimir Putin with the support of the Head of the Republic of Mordovia and PROMOMED Company. The purpose of the center is to localize the development and ensure a full cycle of production of new biotechnological drugs in Russia, including for the treatment of cancer and autoimmune diseases.
PROMOMED provided assistance to the Republican TUBERCULOSIS dispensary in Saransk
The Biochemist plant donated more than 6,000 packages of medicines to the Republican Tuberculosis Dispensary. Among them are drugs for the treatment of tuberculosis, cardiovascular, neurological diseases, as well as antibiotics, antiviral, anti-inflammatory and other drugs.
February
PROMOMED is among the TOP 10 Russian patent holders in the field of pharmaceuticals
PROMOMED entered the TOP 10 of the rating of the leading Russian patent holders in the field of pharmaceuticals of the Eurasian Patent Office. In 2024, the Group registered 20 new patents and filed 46 Russian and international applications for inventions. The number of own trademarks has increased to 550.
PROMOMED has launched the innovative drug Tirzetta® for the treatment of obesity and diabetes mellitus
The drug Tirzetta® (INN: tirzepatide) is the first and only Russian competitor of the well-known and not available in Russia medicinal product Mounjaro and does not contain any preservatives. The revolutionary effect of the drug Tirzetta® consists in a new quality of weight loss – a marked reduction in the volume of adipose tissue while carefully preserving the muscular corset and forming a physiologically correct, "beautiful" silhouette.
The victory of the Chairman of the Board of Directors of PJSC PROMOMED in the XIX national award "Director of the Year" in the nomination "Breakthrough of the Year"
The award recognizes the contribution of independent directors, chairmen and corporate secretaries to the development of corporate governance in Russia. Experts noted the dynamic growth of PROMOMED and the Group's entry into the stock exchange in 2024.
March
PROMOMED is among the best pharmaceutical manufacturers in Russia according to Forbes
PROMOMED entered the TOP 10 of the best pharmaceutical companies in the country in the Forbes rating. PROMOMED's position in the rating is secured by a high indicator of sales dynamics and the result in terms of the number of clinical trials. The rating is published in Forbes Healthcare magazine and is based on data from the AlphaRM research agency.
April
PROMOMED was the first in Russia to attract financing with the help of new format bonds
PROMOMED has placed a new investment product, structural bonds, which provide full capital protection and are linked to the growth of the Company's share price. The volume of attraction amounted to more than 1.6 billion rubles, which confirmed the high interest of investors in the PROMOTIONAL growth strategy and the new investment product.
PROMOMED became the winner of the Platinum Ounce competition in the "Deal of the Year" nomination
Platinum Ounce is one of the oldest professional contests in the Russian pharmaceutical market. Independent experts and the jury of the competition called the successful holding of a PROMOTIONAL IPO and the listing of securities on the Moscow Stock Exchange in 2024 the "Deal of the Year".
PROMOMED has launched the first subscription program in the history of the Russian pharmaceutical industry
The Promeka subscription program allows you to purchase PROMOMED drugs with significant discounts and adhere to the prescribed therapy without interruptions in a comfortable financial regime. By subscribing to the course of treatment recommended by the doctor, the patient receives a systematization of the use of prescribed medications, a convenient reminder service, and significant savings. This will help you get through therapy without unwanted pauses in treatment. The subscription will allow patients to save up to 40% of the cost of the drug during the course of treatment.
May
PROMOMED became the general partner of the National Diabetological Congress -